References
1. Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining
childhood and adolescent cancer mortality. Cancer .
2014;120(16):2497-2506. doi:10.1002/cncr.28748
2. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged
peripheral blood stem-cell transplantation for high-risk neuroblastoma
(COG A3973): a randomised phase 3 trial. Lancet Oncol .
2013;14(10):999-1008. doi:10.1016/S1470-2045(13)70309-7
3. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D.
High-dose rapid and standard induction chemotherapy for patients aged
over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet
Oncol . 2008;9(3):247-256. doi:10.1016/S1470-2045(08)70069-X
4. Kushner BH, Kramer K, Modak S, Cheung NK V. Five-day courses of
irinotecan as palliative therapy for patients with neuroblastoma.Cancer . 2005;103(4):858-862. doi:10.1002/cncr.20846
5. Kushner BH, Kramer K, Modak S, Cheung NK V. Irinotecan plus
temozolomide for relapsed or refractory neuroblastoma. J Clin
Oncol . 2006;24(33):5271-5276. doi:10.1200/JCO.2006.06.7272
6. Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK V.
Ifosfamide, carboplatin, and etoposide for neuroblastoma: A high-dose
salvage regimen and review of the literature. Cancer .
2013;119(3):665-671. doi:10.1002/cncr.27783
7. Saylors RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus
topotecan in children with recurrent or refractory solid tumors: A
pediatric oncology group phase II study. J Clin Oncol .
2001;19(15):3463-3469. doi:10.1200/JCO.2001.19.15.3463
8. Inoue M, Yasui M, Sawada A, et al. Efficacy of combination
chemotherapy consisting of irinotecan, etoposide, and carboplatin (IREC)
in children with refractory solid tumors. Japanese J Pediatr
Oncol . 2007;44(2):135-142.
9. Ando Y, Saka H, Ando M, et al. Polymorphisms of
UDP-glucuronosyltransferase gene and irinotecan toxicity: A
pharmacogenetic analysis. Cancer Res . 2000;60(24):6921-6926.
10. Minami H, Sai K, Saeki M, et al. Irinotecan
pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in
Japanese: Roles of UGT1A1*6 and *28. Pharmacogenet Genomics .
2007;17(7):497-504. doi:10.1097/FPC.0b013e328014341f
11. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the
international criteria for neuroblastoma diagnosis, staging and response
to treatment. Prog Clin Biol Res . 1994;385(8):363-369.
doi:10.1080/16501960410016046
12. Negoro Y, Yano R, Yoshimura M, et al. Influence of UGT1A1
polymorphism on etoposide plus platinum-induced neutropenia in Japanese
patients with small-cell lung cancer. Int J Clin Oncol .
2019;24(3):256-261. doi:10.1007/s10147-018-1358-4
13. Satoh T, Ura T, Yamada Y, et al. Genotype-directed, dose-finding
study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6
polymorphisms. Cancer Sci . 2011;102(10):1868-1873.
doi:10.1111/j.1349-7006.2011.02030.x
14. Kanda Y. Investigation of the freely available easy-to-use software
“EZR” for medical statistics. Bone Marrow Transplant .
2013;48(3):452-458. doi:10.1038/bmt.2012.244
15. Yamasaki S, Tanimoto K, Kohno K, et al. UGT1A1 *6 polymorphism
predicts outcome in elderly patients with relapsed or refractory diffuse
large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide
and irinotecan. Ann Hematol . 2015;94(1):65-69.
doi:10.1007/s00277-014-2170-5